全文获取类型
收费全文 | 199340篇 |
免费 | 2246篇 |
国内免费 | 251篇 |
专业分类
耳鼻咽喉 | 1324篇 |
儿科学 | 7099篇 |
妇产科学 | 3601篇 |
基础医学 | 19012篇 |
口腔科学 | 2042篇 |
临床医学 | 14437篇 |
内科学 | 37920篇 |
皮肤病学 | 1213篇 |
神经病学 | 18529篇 |
特种医学 | 9686篇 |
外科学 | 32749篇 |
综合类 | 2366篇 |
一般理论 | 5篇 |
预防医学 | 18877篇 |
眼科学 | 3053篇 |
药学 | 10715篇 |
中国医学 | 666篇 |
肿瘤学 | 18543篇 |
出版年
2023年 | 209篇 |
2022年 | 314篇 |
2021年 | 776篇 |
2020年 | 488篇 |
2019年 | 653篇 |
2018年 | 22526篇 |
2017年 | 17825篇 |
2016年 | 20071篇 |
2015年 | 1655篇 |
2014年 | 1748篇 |
2013年 | 2076篇 |
2012年 | 8946篇 |
2011年 | 22862篇 |
2010年 | 19872篇 |
2009年 | 12482篇 |
2008年 | 21212篇 |
2007年 | 23295篇 |
2006年 | 2096篇 |
2005年 | 3734篇 |
2004年 | 4804篇 |
2003年 | 5598篇 |
2002年 | 3652篇 |
2001年 | 414篇 |
2000年 | 511篇 |
1999年 | 315篇 |
1998年 | 413篇 |
1997年 | 395篇 |
1996年 | 237篇 |
1995年 | 279篇 |
1994年 | 241篇 |
1993年 | 194篇 |
1992年 | 122篇 |
1991年 | 156篇 |
1990年 | 207篇 |
1989年 | 128篇 |
1988年 | 98篇 |
1987年 | 76篇 |
1986年 | 71篇 |
1985年 | 81篇 |
1984年 | 74篇 |
1983年 | 61篇 |
1982年 | 77篇 |
1981年 | 32篇 |
1980年 | 83篇 |
1979年 | 27篇 |
1974年 | 39篇 |
1938年 | 60篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Beata Gawdis-Wojnarska Marek Brzosko Jacek Fliciński Krzysztof Marlicz Teresa Starzyńska Rodney J Scott Jan Lubiński 《Hereditary cancer in clinical practice》2004,2(2):65-68
Gastric cancer is the second most frequently diagnosed malignancy worldwide and therefore represents a significant healthcare burden. Environmental and genetic factors are involved in the development of gastric cancer. To date only one clear genetic predisposition has been identified involving mutations in the E-cadherin gene. The disease phenotype in patients harbouring E-cadherin mutations appears to be specifically related to diffuse gastric cancer. Little is known genetically about the other forms of gastric cancer. Since there is a growing awareness about the necessity of early intervention criteria have been developed that aid the identification of hereditary forms of gastric cancer. The aim of the current study was to identify minimal inclusion criteria so that nuclear pedigree families can be provided with risk assessment and/or genetic testing.The results reveal that inclusion features described herein such as (a) gastric cancer diagnosed before 46 years of age; (b) two gastric cancers among first degree relatives diagnosed over the age of 50 are useful in identifying suspected hereditary gastric cancer patients. 相似文献
992.
993.
994.
995.
996.
997.
Mitch Dowsett 《Breast cancer research and treatment》2004,87(1):11-18
cDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple
tumor types. These molecules must then be validated as clinically relevant prognostic and predictive markers, and this translational
research is best conducted in the context of clinical trials. Outcomes data and clinical specimens collected in the ‘Arimidex’,
Tamoxifen, Alone or in Combination (ATAC) study, for example, can now be used to compare the expression of biomarkers with
clinical outcomes. In this study, adjuvant tamoxifen and anastrozole (‘Arimidex’) were compared alone and in combination in
more than 9000 women with breast cancer. Anastrozole was found to be superior to tamoxifen in terms of disease-free survival,
time to recurrence, and reduction in the incidence of contralateral tumors. Importantly, tissue specimens from surgical excision,
local relapse, and contralateral breast cancer were collected and paraffin-embedded for storage. In the TA01 (TransATAC) program,
these specimens will be studied (after obtaining patient consent) using tissue microarrays; tissue biopsy cores 0.6 mm in
diameter will be removed from donor blocks and placed on recipient blocks, which will be sectioned to allow the simultaneous
analysis of the same samples for multiple biomarkers. These analyses can help determine differential benefits of treatment
with anastrozole or tamoxifen, depending on the expression of particular biomarkers in tumor cells. This research also should
clarify de novo and acquired resistance mechanisms, and the validation of relevant molecular pathways could guide the development of new
drugs. Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
998.
Objective: To study the gene polymorphisms of GSTT1 and GSTM1 in nasopharyngeal carcinoma (NPC) patients and controls in an
incidental area to evaluate the relationship between specific genotype and genotype combinations of these polymorphisms with
the risk of NPC. Methods: Cases and controls all came from the Southwestern Guangxi. DNAs were extracted from their WBC. PCR
technique was used to calculate the deletion rate of the two detoxific enzyme genes. Results: In this high risk area of NPC,
the residents had high level deletion rates of 47.4% (64/135) Ml and T1 40.7% (55/135). The deletion rates were even higher
in NPC patients, 61.5% (56/91) for Ml and 59.3% (54/91) for T1 respectively. There were statistical significances compared
with control,P<0.05 andP<0.01 for Ml and T1 respectively. The difference was more significant in terms of combined Ml and T1 deletion between patients
and controlsx
2=12.533,P=0.002. Conclusion: The combined deletion of detoxific enzyme genes GSTM1 and GSTT1 may be an important genetic susceptible
factor for NPC in Guangxi.
Biography: DENG Zhuo-lin (1929-), male, professor of pathology, Guangxi Medical University, majors in tumor pathology. E-mail :zhuolin@hotmail.com 相似文献
999.
1000.
Donato Gemmati Alessia Ongaro Gian L Scapoli Matteo Della Porta Silvia Tognazzo Maria L Serino Eros Di Bona Francesco Rodeghiero Giuseppe Gilli Roberto Reverberi Angelo Caruso Michela Pasello Agnese Pellati Monica De Mattei 《Cancer epidemiology, biomarkers & prevention》2004,13(5):787-794
Folate and methionine metabolism is involved in DNA synthesis and methylation processes. Polymorphisms in the genes of folate metabolism enzymes have been associated with some forms of cancer. In a case-control study, we evaluated whether four common polymorphisms in methylenetetrahydrofolate reductase (MTHFR C677T and A1298C), methionine synthase (MS A2756G), and methionine synthase reductase (MTRR A66G) genes may have a role in altering susceptibility to adult acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). We analyzed DNA of 120 adult ALL, 200 NHL, and 257 healthy control subjects. Individual carrying the MTHFR 677TT genotype showed a 3.6-fold decreased ALL risk [odds ratio (OR) 0.28, 95% confidence interval (95% CI) 0.12-0.72] than wild-types. Similarly, MS 2756GG individuals showed a 5.0-fold decreased ALL risk (OR 0.20, 95% CI 0.02-1.45) than wild-types. In combined results, subjects with the MTHFR 677CT/TT and MS 2756AG/GG genotypes revealed a 3.6-fold ALL risk reduction (OR 0.28, 95% CI 0.14-0.58) and those with the MTHFR 677TT and MTRR 66AG genotypes revealed a 4.2-fold ALL risk reduction (OR 0.24, 95% CI 0.06-0.81). Finally, those with the MS 2756AG/GG and MTRR 66AG/GG genotypes revealed a 2.2-fold ALL risk reduction (OR 0.45, 95% CI 0.10-0.85). Single analysis for NHL did not show any significant difference for all the polymorphisms investigated, but in the low-grade NHL subgroup, we found a 2.0-fold risk reduction for the MTRR 66GG homozygous genotype (OR 0.50, 95% CI 0.25-0.99), which was higher (OR 0.37, 95% CI 0.14-0.85) when analyzed in combination with MS 2756AA genotype. These data are in accordance with the hypothesis that polymorphisms in the genes for folate and methionine metabolism might play a greater role in the occurrence of ALL than NHL by influencing DNA synthesis and/or DNA methylation. 相似文献